Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 DLL3 (Rovalpituzumab) h(28ζ), which is constructed for the engineering of T cells to target human DLL3. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-DLL3 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Lung malignancy.
|
CAR Construction :
Fig.1 Flow cytometric analysis of rova-IR700 in SBC3 and HBEC cells. DLL3 expression in SBC3 cells was evident, while fluorescence was essentially absent in the DLL3-negative. Isobe, Y., Sato, K., Nishinaga, Y., Takahashi, K., Taki, S., Yasui, H., ... & Hasegawa, Y. (2020). Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. EBioMedicine, 52, 102632. |
|
CAR Construction :
Fig.2 Examination of DLL3 expression in the chemoresistant SCLC cell lines, H69/CDDP, H69/VP, SBC3/CDDP, SBC3/ETP, and SBC3 /SN38. All measurements were performed in triplicate. Isobe, Y., Sato, K., Nishinaga, Y., Takahashi, K., Taki, S., Yasui, H., ... & Hasegawa, Y. (2020). Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. EBioMedicine, 52, 102632. |
|
CAR Construction :
Fig.3 DLL3/CD3 ITE–induced apoptosis of SCLC cells. Human PBMCs were cocultivated with DLL3-positive SHP-77 cells and increasing concentrations of DLL3/CD3 ITE at an E:T of 10:1 for 24 hours. Each datapoint represents a single measurement. Hipp, S., Voynov, V., Drobits-Handl, B., Giragossian, C., Trapani, F., Nixon, A. E., ... & Adam, P. J. (2020). A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung CancerA Novel DLL3-Targeted IgG-Like T-Cell Engager. Clinical Cancer Research, 26(19), 5258-5268. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-DLL3 (Rovalpituzumab) h(CD28-CD3ζ) CAR, pSBCAR1 (CAR-SB-LX0197). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
